ID   SRC_MOUSE               Reviewed;         541 AA.
AC   P05480; Q2M4I4;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   27-JUL-2011, sequence version 4.
DT   04-FEB-2015, entry version 167.
DE   RecName: Full=Neuronal proto-oncogene tyrosine-protein kinase Src;
DE            EC=2.7.10.2;
DE   AltName: Full=Proto-oncogene c-Src;
DE   AltName: Full=pp60c-src;
DE            Short=p60-Src;
GN   Name=Src;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=BALB/c;
RX   PubMed=2440106; DOI=10.1126/science.2440106;
RA   Martinez R., Mathey-Prevot B., Bernards A., Baltimore D.;
RT   "Neuronal pp60c-src contains a six-amino acid insertion relative to
RT   its non-neuronal counterpart.";
RL   Science 237:411-415(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=CAST/EiJ; TISSUE=Brain;
RA   Farber C.R., Corva P.M., Medrano J.F.;
RT   "Characterization of quantitative trait loci influencing growth and
RT   adiposity using congenic mouse strains.";
RL   Submitted (JAN-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=C57BL/6J;
RX   PubMed=19468303; DOI=10.1371/journal.pbio.1000112;
RA   Church D.M., Goodstadt L., Hillier L.W., Zody M.C., Goldstein S.,
RA   She X., Bult C.J., Agarwala R., Cherry J.L., DiCuccio M., Hlavina W.,
RA   Kapustin Y., Meric P., Maglott D., Birtle Z., Marques A.C., Graves T.,
RA   Zhou S., Teague B., Potamousis K., Churas C., Place M., Herschleb J.,
RA   Runnheim R., Forrest D., Amos-Landgraf J., Schwartz D.C., Cheng Z.,
RA   Lindblad-Toh K., Eichler E.E., Ponting C.P.;
RT   "Lineage-specific biology revealed by a finished genome assembly of
RT   the mouse.";
RL   PLoS Biol. 7:E1000112-E1000112(2009).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Adams M.D., Myers E.W., Smith H.O., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   INTERACTION WITH CSF1R.
RX   PubMed=7681396;
RA   Courtneidge S.A., Dhand R., Pilat D., Twamley G.M., Waterfield M.D.,
RA   Roussel M.F.;
RT   "Activation of Src family kinases by colony stimulating factor-1, and
RT   their association with its receptor.";
RL   EMBO J. 12:943-950(1993).
RN   [6]
RP   INTERACTION WITH ERBB2.
RX   PubMed=7542762;
RA   Muthuswamy S.K., Muller W.J.;
RT   "Direct and specific interaction of c-Src with Neu is involved in
RT   signaling by the epidermal growth factor receptor.";
RL   Oncogene 11:271-279(1995).
RN   [7]
RP   FUNCTION IN IL11-SIGNALING.
RX   PubMed=8641341;
RA   Fuhrer D.K., Yang Y.C.;
RT   "Activation of Src-family protein tyrosine kinases and
RT   phosphatidylinositol 3-kinase in 3T3-L1 mouse preadipocytes by
RT   interleukin-11.";
RL   Exp. Hematol. 24:195-203(1996).
RN   [8]
RP   ENZYME REGULATION.
RX   PubMed=8910389; DOI=10.1074/jbc.271.44.27895;
RA   Rodriguez-Fernandez J.L., Rozengurt E.;
RT   "Bombesin, bradykinin, vasopressin, and phorbol esters rapidly and
RT   transiently activate Src family tyrosine kinases in Swiss 3T3 cells.
RT   Dissociation from tyrosine phosphorylation of p125 focal adhesion
RT   kinase.";
RL   J. Biol. Chem. 271:27895-27901(1996).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH STAT1.
RX   PubMed=9344858; DOI=10.1006/bbrc.1997.7493;
RA   Cirri P., Chiarugi P., Marra F., Raugei G., Camici G., Manao G.,
RA   Ramponi G.;
RT   "c-Src activates both STAT1 and STAT3 in PDGF-stimulated NIH3T3
RT   cells.";
RL   Biochem. Biophys. Res. Commun. 239:493-497(1997).
RN   [10]
RP   INTERACTION WITH DDEF1/ASAP1.
RX   PubMed=9819391;
RA   Brown M.T., Andrade J., Radhakrishna H., Donaldson J.G., Cooper J.A.,
RA   Randazzo P.A.;
RT   "ASAP1, a phospholipid-dependent arf GTPase-activating protein that
RT   associates with and is phosphorylated by Src.";
RL   Mol. Cell. Biol. 18:7038-7051(1998).
RN   [11]
RP   IDENTIFICATION IN A COMPLEX WITH NCAM1; CDH2; PLCG1; FRS2; FGFR4;
RP   SHC1; GAP43 AND CTTN.
RX   PubMed=11433297; DOI=10.1038/35083041;
RA   Cavallaro U., Niedermeyer J., Fuxa M., Christofori G.;
RT   "N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-
RT   receptor signalling.";
RL   Nat. Cell Biol. 3:650-657(2001).
RN   [12]
RP   INTERACTION WITH PDGFRA.
RX   PubMed=14644164; DOI=10.1016/j.yexcr.2003.08.001;
RA   Avrov K., Kazlauskas A.;
RT   "The role of c-Src in platelet-derived growth factor alpha receptor
RT   internalization.";
RL   Exp. Cell Res. 291:426-434(2003).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12615910; DOI=10.1083/jcb.200209098;
RA   Miyazaki T., Neff L., Tanaka S., Horne W.C., Baron R.;
RT   "Regulation of cytochrome c oxidase activity by c-Src in
RT   osteoclasts.";
RL   J. Cell Biol. 160:709-718(2003).
RN   [14]
RP   INTERACTION WITH EPHB1.
RX   PubMed=12925710; DOI=10.1083/jcb.200302073;
RA   Vindis C., Cerretti D.P., Daniel T.O., Huynh-Do U.;
RT   "EphB1 recruits c-Src and p52Shc to activate MAPK/ERK and promote
RT   chemotaxis.";
RL   J. Cell Biol. 162:661-671(2003).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH PTK2B/PYK2.
RX   PubMed=14739300; DOI=10.1074/jbc.M311032200;
RA   Miyazaki T., Sanjay A., Neff L., Tanaka S., Horne W.C., Baron R.;
RT   "Src kinase activity is essential for osteoclast function.";
RL   J. Biol. Chem. 279:17660-17666(2004).
RN   [16]
RP   INTERACTION WITH FLT3.
RX   PubMed=16684964; DOI=10.1182/blood-2005-07-008896;
RA   Heiss E., Masson K., Sundberg C., Pedersen M., Sun J., Bengtsson S.,
RA   Ronnstrand L.;
RT   "Identification of Y589 and Y599 in the juxtamembrane domain of Flt3
RT   as ligand-induced autophosphorylation sites involved in binding of Src
RT   family kinases and the protein tyrosine phosphatase SHP2.";
RL   Blood 108:1542-1550(2006).
RN   [17]
RP   INTERACTION WITH CCPG1.
RX   PubMed=17000758; DOI=10.1128/MCB.00670-06;
RA   Kostenko E.V., Olabisi O.O., Sahay S., Rodriguez P.L., Whitehead I.P.;
RT   "Ccpg1, a novel scaffold protein that regulates the activity of the
RT   Rho guanine nucleotide exchange factor Dbs.";
RL   Mol. Cell. Biol. 26:8964-8975(2006).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-192, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain;
RX   PubMed=18034455; DOI=10.1021/pr0701254;
RA   Ballif B.A., Carey G.R., Sunyaev S.R., Gygi S.P.;
RT   "Large-scale identification and evolution indexing of tyrosine
RT   phosphorylation sites from murine brain.";
RL   J. Proteome Res. 7:311-318(2008).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19144319; DOI=10.1016/j.immuni.2008.11.006;
RA   Trost M., English L., Lemieux S., Courcelles M., Desjardins M.,
RA   Thibault P.;
RT   "The phagosomal proteome in interferon-gamma-activated macrophages.";
RL   Immunity 30:143-154(2009).
RN   [20]
RP   INTERACTION WITH ARRB2.
RX   PubMed=19122674; DOI=10.1038/nature07617;
RA   Luan B., Zhao J., Wu H., Duan B., Shu G., Wang X., Li D., Jia W.,
RA   Kang J., Pei G.;
RT   "Deficiency of a beta-arrestin-2 signal complex contributes to insulin
RT   resistance.";
RL   Nature 457:1146-1149(2009).
RN   [21]
RP   INTERACTION WITH DDR1.
RX   PubMed=20093046; DOI=10.1016/j.carpath.2009.12.006;
RA   Lu K.K., Trcka D., Bendeck M.P.;
RT   "Collagen stimulates discoidin domain receptor 1-mediated migration of
RT   smooth muscle cells through Src.";
RL   Cardiovasc. Pathol. 20:71-76(2011).
RN   [22]
RP   REVIEW ON FUNCTION.
RX   PubMed=8672527; DOI=10.1016/0304-419X(96)00003-0;
RA   Brown M.T., Cooper J.A.;
RT   "Regulation, substrates and functions of src.";
RL   Biochim. Biophys. Acta 1287:121-149(1996).
RN   [23]
RP   REVIEW ON FUNCTION.
RX   PubMed=9442882; DOI=10.1146/annurev.cellbio.13.1.513;
RA   Thomas S.M., Brugge J.S.;
RT   "Cellular functions regulated by Src family kinases.";
RL   Annu. Rev. Cell Dev. Biol. 13:513-609(1997).
RN   [24]
RP   REVIEW ON FUNCTION.
RX   PubMed=11964124; DOI=10.1007/s00018-002-8438-2;
RA   Ma Y.C., Huang X.Y.;
RT   "Novel regulation and function of Src tyrosine kinase.";
RL   Cell. Mol. Life Sci. 59:456-462(2002).
CC   -!- FUNCTION: Non-receptor protein tyrosine kinase which is activated
CC       following engagement of many different classes of cellular
CC       receptors including immune response receptors, integrins and other
CC       adhesion receptors, receptor protein tyrosine kinases, G protein-
CC       coupled receptors as well as cytokine receptors. Participates in
CC       signaling pathways that control a diverse spectrum of biological
CC       activities including gene transcription, immune response, cell
CC       adhesion, cell cycle progression, apoptosis, migration, and
CC       transformation. Due to functional redundancy between members of
CC       the SRC kinase family, identification of the specific role of each
CC       SRC kinase is very difficult. SRC appears to be one of the primary
CC       kinases activated following engagement of receptors and plays a
CC       role in the activation of other protein tyrosine kinase (PTK)
CC       families. Receptor clustering or dimerization leads to recruitment
CC       of SRC to the receptor complexes where it phosphorylates the
CC       tyrosine residues within the receptor cytoplasmic domains. Plays
CC       an important role in the regulation of cytoskeletal organization
CC       through phosphorylation of specific substrates such as AFAP1.
CC       Phosphorylation of AFAP1 allows the SRC SH2 domain to bind AFAP1
CC       and to localize to actin filaments. Cytoskeletal reorganization is
CC       also controlled through the phosphorylation of cortactin (CTTN).
CC       When cells adhere via focal adhesions to the extracellular matrix,
CC       signals are transmitted by integrins into the cell resulting in
CC       tyrosine phosphorylation of a number of focal adhesion proteins,
CC       including PTK2/FAK1 and paxillin (PXN). In addition to
CC       phosphorylating focal adhesion proteins, SRC is also active at the
CC       sites of cell-cell contact adherens junctions and phosphorylates
CC       substrates such as beta-catenin (CTNNB1), delta-catenin (CTNND1),
CC       and plakoglobin (JUP). Another type of cell-cell junction, the gap
CC       junction, is also a target for SRC, which phosphorylates connexin-
CC       43 (GJA1). SRC is implicated in regulation of pre-mRNA-processing
CC       and phosphorylates RNA-binding proteins such as KHDRBS1. Also
CC       plays a role in PDGF-mediated tyrosine phosphorylation of both
CC       STAT1 and STAT3, leading to increased DNA binding activity of
CC       these transcription factors. Involved in the RAS pathway through
CC       phosphorylation of RASA1 and RASGRF1. Plays a role in EGF-mediated
CC       calcium-activated chloride channel activation. Required for
CC       epidermal growth factor receptor (EGFR) internalization through
CC       phosphorylation of clathrin heavy chain (CLTC and CLTCL1) at 'Tyr-
CC       1477'. Involved in beta-arrestin (ARRB1 and ARRB2) desensitization
CC       through phosphorylation and activation of ADRBK1, leading to beta-
CC       arrestin phosphorylation and internalization. Has a critical role
CC       in the stimulation of the CDK20/MAPK3 mitogen-activated protein
CC       kinase cascade by epidermal growth factor. Might be involved not
CC       only in mediating the transduction of mitogenic signals at the
CC       level of the plasma membrane but also in controlling progression
CC       through the cell cycle via interaction with regulatory proteins in
CC       the nucleus. Plays an important role in osteoclastic bone
CC       resorption in conjunction with PTK2B/PYK2. Both the formation of a
CC       SRC-PTK2B/PYK2 complex and SRC kinase activity are necessary for
CC       this function. Recruited to activated integrins by PTK2B/PYK2,
CC       thereby phosphorylating CBL, which in turn induces the activation
CC       and recruitment of phosphatidylinositol 3-kinase to the cell
CC       membrane in a signaling pathway that is critical for osteoclast
CC       function. Promotes energy production in osteoclasts by activating
CC       mitochondrial cytochrome C oxidase. Phosphorylates DDR2 on
CC       tyrosine residues, thereby promoting its subsequent
CC       autophosphorylation. Phosphorylates RUNX3 and COX2 on tyrosine
CC       residues, TNK2 on 'Tyr-284' and CBL on 'Tyr-731'. Enhances
CC       DDX58/RIG-I-elicited antiviral signaling. Phosphorylates PDPK1 at
CC       'Tyr-9', 'Tyr-373' and 'Tyr-376'. Phosphorylates BCAR1 at 'Tyr-
CC       132'. Phosphorylates CBLC at multiple tyrosine residues,
CC       phosphorylation at 'Tyr-341' activates CBLC E3 activity.
CC       {ECO:0000269|PubMed:12615910, ECO:0000269|PubMed:14739300,
CC       ECO:0000269|PubMed:8641341, ECO:0000269|PubMed:9344858}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: Phosphorylation by CSK at Tyr-535 inhibits
CC       kinase activity. Inhibitory phosphorylation at Tyr-535 is enhanced
CC       by heme. Further phosphorylation by CDK1 partially reactivates
CC       CSK-inactivated SRC and facilitates complete reactivation by
CC       protein tyrosine phosphatase PTPRC. Integrin engagement stimulates
CC       kinase activity. Phosphorylation by PTK2/FAK1 enhances kinase
CC       activity. Butein and pseudosubstrate-based peptide inhibitors like
CC       CIYKYYF act as inhibitors. Phosphorylation at Tyr-424 increases
CC       kinase activity. {ECO:0000269|PubMed:8910389}.
CC   -!- SUBUNIT: Interacts with CDCP1, PELP1, TGFB1I1 and TOM1L2.
CC       Interacts with DDEF1/ASAP1 via its SH3 domain. Interacts with
CC       CCPG1. Interacts with the cytoplasmic domain of MUC1,
CC       phosphorylates it and increases binding of MUC1 with beta-catenin.
CC       Interacts with RALGPS1 via its SH3 domain. Interacts with CAV2
CC       (tyrosine phosphorylated form). Interacts (via the SH3 domain and
CC       the protein kinase domain) with ARRB1; the interaction is
CC       independent of the phosphorylation state of SRC C-terminus.
CC       Interacts with FCAMR and PXN. Interacts with ARRB2. Interacts with
CC       ARRB1. Interacts with SRCIN1. Interacts with SRCIN1. Interacts
CC       with NDFIP2 and more weakly with NDFIP1. Interacts with PIK3CA
CC       and/or PIK3C2B, PTK2/FAK1, ESR1 (dimethylated on arginine) and
CC       FAK. Interacts (via SH2 and SH3 domain) with TNK2. Interacts (via
CC       protein kinase domain) with the tyrosine phosphorylated form of
CC       RUNX3 (via runt domain). Interacts with TRAF3 (via RING-type zinc
CC       finger domain). Interacts with DDX58, MAVS and TBK1. Interacts
CC       (via SH2 domain) with GNB2L1/RACK1; the interaction is enhanced by
CC       tyrosine phosphorylation of GNB2L1 and inhibits SRC activity.
CC       Interacts (via SH2 domain) with the 'Tyr-402' phosphorylated form
CC       of PTK2B/PYK2. Interacts (via SH2 domain) with FLT3 (tyrosine
CC       phosphorylated). Identified in a complex containing FGFR4, NCAM1,
CC       CDH2, PLCG1, FRS2, SRC, SHC1, GAP43 and CTTN. Interacts with
CC       EPHB1; activates the MAPK/ERK cascade to regulate cell migration.
CC       Interacts with ERBB2 and STAT1. Interacts with PDGFRA (tyrosine
CC       phosphorylated). Interacts with CSF1R. Interacts (via SH2 domain)
CC       with the 'Tyr-9' phosphorylated form of PDPK1. Interacts with
CC       DDR2. Interacts with AMOTL2; this interaction regulates the
CC       translocation of phosphorylated SRC to peripheral cell-matrix
CC       adhesion sites. Interacts with DDR1 and DAB2. Interacts with
CC       TRAP1. Interacts with CBLC; the interaction is enhanced when SRC
CC       is phosphorylated at 'Tyr-424'. {ECO:0000269|PubMed:11433297,
CC       ECO:0000269|PubMed:12925710, ECO:0000269|PubMed:14644164,
CC       ECO:0000269|PubMed:14739300, ECO:0000269|PubMed:16684964,
CC       ECO:0000269|PubMed:17000758, ECO:0000269|PubMed:19122674,
CC       ECO:0000269|PubMed:20093046, ECO:0000269|PubMed:7542762,
CC       ECO:0000269|PubMed:7681396, ECO:0000269|PubMed:9344858,
CC       ECO:0000269|PubMed:9819391}.
CC   -!- INTERACTION:
CC       Q63767:Bcar1 (xeno); NbExp=2; IntAct=EBI-298680, EBI-1176801;
CC       P07141:Csf1; NbExp=2; IntAct=EBI-298680, EBI-777188;
CC       P31016:Dlg4 (xeno); NbExp=9; IntAct=EBI-298680, EBI-375655;
CC       Q8T4F7:ena (xeno); NbExp=2; IntAct=EBI-298680, EBI-466810;
CC       P54763:Ephb2; NbExp=3; IntAct=EBI-298680, EBI-537711;
CC       Q00959:Grin2a (xeno); NbExp=5; IntAct=EBI-298680, EBI-630970;
CC       P05106:ITGB3 (xeno); NbExp=5; IntAct=EBI-298680, EBI-702847;
CC       Q05397:PTK2 (xeno); NbExp=5; IntAct=EBI-298680, EBI-702142;
CC       P18052:Ptpra; NbExp=2; IntAct=EBI-298680, EBI-6597520;
CC       P49023:PXN (xeno); NbExp=2; IntAct=EBI-298680, EBI-702209;
CC       Q01973:ROR1 (xeno); NbExp=3; IntAct=EBI-298680, EBI-6082337;
CC       P70315:Was; NbExp=2; IntAct=EBI-298680, EBI-644195;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:12615910}.
CC       Mitochondrion inner membrane {ECO:0000269|PubMed:12615910}.
CC       Nucleus {ECO:0000269|PubMed:12615910}. Cytoplasm, cytoskeleton
CC       {ECO:0000269|PubMed:12615910}. Note=Localizes to focal adhesion
CC       sites after integrin engagement. Localization to focal adhesion
CC       sites requires myristoylation and the SH3 domain.
CC   -!- PTM: Myristoylated at Gly-2, and this is essential for targeting
CC       to membranes. {ECO:0000250}.
CC   -!- PTM: Dephosphorylated at Tyr-535 by PTPRJ (By similarity).
CC       Phosphorylated on Tyr-535 by c-Src kinase (CSK). The
CC       phosphorylated form is termed pp60c-src. Dephosphorylated by PTPRJ
CC       at Tyr-424. Normally maintained in an inactive conformation with
CC       the SH2 domain engaged with Tyr-535, the SH3 domain engaged with
CC       the SH2-kinase linker, and Tyr-424 dephosphorylated.
CC       Dephosphorylation of Tyr-535 as a result of protein tyrosine
CC       phosphatase (PTP) action disrupts the intramolecular interaction
CC       between the SH2 domain and Tyr-535, Tyr-424 can then become
CC       autophosphorylated, resulting in SRC activation. Phosphorylation
CC       of Tyr-535 by CSK allows this interaction to reform, resulting in
CC       SRC inactivation. CDK5-mediated phosphorylation at Ser-74 targets
CC       SRC to ubiquitin-dependent degradation and thus leads to
CC       cytoskeletal reorganization. Phosphorylated by PTK2/FAK1; this
CC       enhances kinase activity. Phosphorylated by PTK2B/PYK2; this
CC       enhances kinase activity (By similarity). {ECO:0000250}.
CC   -!- PTM: S-nitrosylation is important for activation of its kinase
CC       activity. {ECO:0000250}.
CC   -!- PTM: Ubiquitinated in response to CDK5-mediated phosphorylation.
CC       Ubiquitination mediated by CBLC requires SRC autophosphorylation
CC       at Tyr-424 and may lead to lysosomal degradation (By similarity).
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. SRC subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 SH2 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00191}.
CC   -!- SIMILARITY: Contains 1 SH3 domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00192}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M17031; AAA40135.1; -; mRNA.
DR   EMBL; AY902331; AAX90616.1; -; Genomic_DNA.
DR   EMBL; AL672259; CAM16141.1; -; Genomic_DNA.
DR   EMBL; CH466551; EDL06234.1; -; Genomic_DNA.
DR   CCDS; CCDS38305.1; -.
DR   PIR; A43610; A43610.
DR   RefSeq; NP_001020566.1; NM_001025395.2.
DR   RefSeq; NP_033297.2; NM_009271.3.
DR   UniGene; Mm.22845; -.
DR   ProteinModelPortal; P05480; -.
DR   SMR; P05480; 56-541.
DR   BioGrid; 203491; 41.
DR   DIP; DIP-31071N; -.
DR   IntAct; P05480; 28.
DR   MINT; MINT-85032; -.
DR   STRING; 10090.ENSMUSP00000105155; -.
DR   BindingDB; P05480; -.
DR   ChEMBL; CHEMBL3074; -.
DR   PhosphoSite; P05480; -.
DR   MaxQB; P05480; -.
DR   PaxDb; P05480; -.
DR   PRIDE; P05480; -.
DR   Ensembl; ENSMUST00000092576; ENSMUSP00000090237; ENSMUSG00000027646.
DR   Ensembl; ENSMUST00000109529; ENSMUSP00000105155; ENSMUSG00000027646.
DR   GeneID; 20779; -.
DR   KEGG; mmu:20779; -.
DR   UCSC; uc008npa.1; mouse.
DR   CTD; 6714; -.
DR   MGI; MGI:98397; Src.
DR   eggNOG; COG0515; -.
DR   GeneTree; ENSGT00760000118938; -.
DR   HOGENOM; HOG000233858; -.
DR   HOVERGEN; HBG008761; -.
DR   InParanoid; P05480; -.
DR   KO; K05704; -.
DR   OMA; CHRLTNV; -.
DR   OrthoDB; EOG7GTT2V; -.
DR   BRENDA; 2.7.10.2; 3474.
DR   Reactome; REACT_188191; Signaling by ERBB2.
DR   Reactome; REACT_188578; Signaling by SCF-KIT.
DR   Reactome; REACT_196487; FCGR activation.
DR   Reactome; REACT_198526; Spry regulation of FGF signaling.
DR   Reactome; REACT_204081; CD28 co-stimulation.
DR   Reactome; REACT_206286; GAB1 signalosome.
DR   Reactome; REACT_207601; p38MAPK events.
DR   Reactome; REACT_220322; Thrombin signalling through proteinase activated receptors (PARs).
DR   Reactome; REACT_224600; c-src mediated regulation of Cx43 function and closure of gap junctions.
DR   Reactome; REACT_227425; Regulation of KIT signaling.
DR   Reactome; REACT_230639; Downstream signal transduction.
DR   Reactome; REACT_237796; NCAM signaling for neurite out-growth.
DR   Reactome; REACT_240371; p130Cas linkage to MAPK signaling for integrins.
DR   Reactome; REACT_241951; Ephrin signaling.
DR   Reactome; REACT_242976; Signaling by EGFR.
DR   Reactome; REACT_243212; DSCAM interactions.
DR   Reactome; REACT_243590; EPH-ephrin mediated repulsion of cells.
DR   Reactome; REACT_243939; EPHA-mediated growth cone collapse.
DR   Reactome; REACT_245086; VEGFR2 mediated cell proliferation.
DR   Reactome; REACT_245546; GP1b-IX-V activation signalling.
DR   Reactome; REACT_246176; Integrin alphaIIb beta3 signaling.
DR   Reactome; REACT_248291; DCC mediated attractive signaling.
DR   Reactome; REACT_253341; Netrin mediated repulsion signals.
DR   Reactome; REACT_257088; VEGFA-VEGFR2 Pathway.
DR   Reactome; REACT_257656; EPHB-mediated forward signaling.
DR   Reactome; REACT_257923; Recycling pathway of L1.
DR   Reactome; REACT_258158; EPH-Ephrin signaling.
DR   Reactome; REACT_259068; ADP signalling through P2Y purinoceptor 1.
DR   Reactome; REACT_261568; CTLA4 inhibitory signaling.
DR   ChiTaRS; Src; mouse.
DR   NextBio; 299503; -.
DR   PRO; PR:P05480; -.
DR   Proteomes; UP000000589; Chromosome 2.
DR   Bgee; P05480; -.
DR   CleanEx; MM_SRC; -.
DR   ExpressionAtlas; P05480; baseline and differential.
DR   Genevestigator; P05480; -.
DR   GO; GO:0005884; C:actin filament; IDA:MGI.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:MGI.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0032587; C:ruffle membrane; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046875; F:ephrin receptor binding; IPI:UniProtKB.
DR   GO; GO:0070851; F:growth factor receptor binding; IBA:GO_Central.
DR   GO; GO:0020037; F:heme binding; ISS:UniProtKB.
DR   GO; GO:0051427; F:hormone receptor binding; IBA:GO_Central.
DR   GO; GO:0016301; F:kinase activity; IMP:MGI.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:MGI.
DR   GO; GO:0004672; F:protein kinase activity; IDA:MGI.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IMP:MGI.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:BHF-UCL.
DR   GO; GO:0086098; P:angiotensin-activated signaling pathway involved in heart process; IGI:BHF-UCL.
DR   GO; GO:0045453; P:bone resorption; IMP:UniProtKB.
DR   GO; GO:0060444; P:branching involved in mammary gland duct morphogenesis; IMP:MGI.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0016477; P:cell migration; IMP:MGI.
DR   GO; GO:0071375; P:cellular response to peptide hormone stimulus; IGI:BHF-UCL.
DR   GO; GO:0036120; P:cellular response to platelet-derived growth factor stimulus; IDA:MGI.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IGI:MGI.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0030900; P:forebrain development; IGI:MGI.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0035556; P:intracellular signal transduction; IGI:MGI.
DR   GO; GO:2001237; P:negative regulation of extrinsic apoptotic signaling pathway; IBA:GO_Central.
DR   GO; GO:2001243; P:negative regulation of intrinsic apoptotic signaling pathway; IBA:GO_Central.
DR   GO; GO:0048477; P:oogenesis; IMP:MGI.
DR   GO; GO:0036035; P:osteoclast development; IGI:MGI.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:MGI.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IGI:MGI.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:BHF-UCL.
DR   GO; GO:0071803; P:positive regulation of podosome assembly; IDA:MGI.
DR   GO; GO:0050847; P:progesterone receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:MGI.
DR   GO; GO:0051726; P:regulation of cell cycle; IBA:GO_Central.
DR   GO; GO:0060491; P:regulation of cell projection assembly; IGI:MGI.
DR   GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
DR   GO; GO:0033146; P:regulation of intracellular estrogen receptor signaling pathway; IMP:MGI.
DR   GO; GO:0043393; P:regulation of protein binding; IDA:MGI.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IDA:MGI.
DR   GO; GO:0060065; P:uterus development; IMP:MGI.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Cell adhesion; Cell cycle; Cell membrane;
KW   Complete proteome; Cytoplasm; Cytoskeleton; Immunity; Kinase;
KW   Lipoprotein; Membrane; Mitochondrion; Mitochondrion inner membrane;
KW   Myristate; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Proto-oncogene; Reference proteome; SH2 domain; SH3 domain;
KW   Transferase; Tyrosine-protein kinase; Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000250}.
FT   CHAIN         2    541       Neuronal proto-oncogene tyrosine-protein
FT                                kinase Src.
FT                                /FTId=PRO_0000088142.
FT   DOMAIN       83    150       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN      156    253       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      275    528       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     281    289       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    394    394       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     303    303       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES      17     17       Phosphoserine. {ECO:0000250}.
FT   MOD_RES      34     34       Phosphoserine. {ECO:0000250}.
FT   MOD_RES      68     68       Phosphoserine. {ECO:0000250}.
FT   MOD_RES      73     73       Phosphothreonine. {ECO:0000250}.
FT   MOD_RES      74     74       Phosphoserine; by CDK5. {ECO:0000250}.
FT   MOD_RES     192    192       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:18034455}.
FT   MOD_RES     424    424       Phosphotyrosine; by autocatalysis;
FT                                alternate. {ECO:0000250}.
FT   MOD_RES     424    424       Phosphotyrosine; by FAK2; alternate.
FT                                {ECO:0000250}.
FT   MOD_RES     444    444       Phosphotyrosine. {ECO:0000250}.
FT   MOD_RES     516    516       Phosphothreonine. {ECO:0000250}.
FT   MOD_RES     527    527       Phosphotyrosine. {ECO:0000250}.
FT   MOD_RES     535    535       Phosphotyrosine; by CSK. {ECO:0000250}.
FT   LIPID         2      2       N-myristoyl glycine. {ECO:0000250}.
FT   CONFLICT     80     80       P -> A (in Ref. 1; AAA40135).
FT                                {ECO:0000305}.
SQ   SEQUENCE   541 AA;  60645 MW;  0534AF027783BCCF CRC64;
     MGSNKSKPKD ASQRRRSLEP SENVHGAGGA FPASQTPSKP ASADGHRGPS AAFVPPAAEP
     KLFGGFNSSD TVTSPQRAGP LAGGVTTFVA LYDYESRTET DLSFKKGERL QIVNNTRKVD
     VREGDWWLAH SLSTGQTGYI PSNYVAPSDS IQAEEWYFGK ITRRESERLL LNAENPRGTF
     LVRESETTKG AYCLSVSDFD NAKGLNVKHY KIRKLDSGGF YITSRTQFNS LQQLVAYYSK
     HADGLCHRLT TVCPTSKPQT QGLAKDAWEI PRESLRLEVK LGQGCFGEVW MGTWNGTTRV
     AIKTLKPGTM SPEAFLQEAQ VMKKLRHEKL VQLYAVVSEE PIYIVTEYMN KGSLLDFLKG
     ETGKYLRLPQ LVDMSAQIAS GMAYVERMNY VHRDLRAANI LVGENLVCKV ADFGLARLIE
     DNEYTARQGA KFPIKWTAPE AALYGRFTIK SDVWSFGILL TELTTKGRVP YPGMVNREVL
     DQVERGYRMP CPPECPESLH DLMCQCWRKE PEERPTFEYL QAFLEDYFTS TEPQYQPGEN
     L
//
